DEXWireNews

Trevena, Inc. Bullish Targets

Long
NASDAQ:TRVN   Trevena, Inc.
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our App on Google Play! dexwirenews.com/APP

2) Text Message Notifications: dexwirenews.com/SMS

3) Telegram: t.me/DEXWireNews

4) Follow Us on our Social Networks
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.